By leveraging nanotechnology to deliver cGAS‐STING agonists and augmenting the innate immune response, this method complements the action of genetically modified CAR‐T cells, which are engineered to precisely target and eradicate tumor cells [66]. This evidence concerns the gene STING1 and neoplasm.